Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alcon ( (CH:ALC) ) has provided an update.
On January 6, 2026, Alcon terminated its definitive merger agreement to acquire STAAR Surgical Company, originally announced on August 5, 2025, signaling a strategic decision to walk away from the deal after reassessing price and risk. Chief executive David J. Endicott stressed that the move does not alter Alcon’s refractive strategy, highlighting that the company will continue to focus on its new wavelight plus platform for LASIK and on the global rollout of more than 10 major surgical and vision care products this year, a push that is expected to reinforce its competitive position in refractive surgery and broader eye care markets while offering continued innovation for patients and eye care professionals.
The most recent analyst rating on (CH:ALC) stock is a Sell with a CHF60.00 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon Inc., based in Switzerland, is a global leader in eye care with a heritage of more than 75 years. The company offers one of the broadest portfolios of surgical and vision care products, addressing conditions such as cataracts, glaucoma, retinal diseases and refractive errors, and reaches more than 260 million people in over 140 countries through its network of over 25,000 associates and partnerships with eye care professionals.
Average Trading Volume: 1,244,111
Technical Sentiment Signal: Sell
Current Market Cap: CHF31.75B
See more data about ALC stock on TipRanks’ Stock Analysis page.